Our Main Focus:
Targeting glial cells in neuropsychiatric pathologies
We have a long-standing experience employing next generation drug discovery approaches for promoting brain rejuvination and regeneration using in vitro, ex-vivo and in vivo models. We have vastly improved on our published hallmark pipeline by screening cell specific and disease specific databases coupled with sophisticated AI tools to identify novel targets and treatment options.
Our goals are clear: Our drug discovery efforts helps overcoming limits associated with traditional drug screening efforts and increase the success of clinical trials.
Precision medicine for
neuropyschiatric & neurological diseases
There are no successful therapies for treating the majority of neuropsychiatric and neurodegenerative diseases. In order to address these unmet needs, our drug discovery workflow have been tailored to support the Biotech community for deriving novel therapies which will promote the regeneration of damaged neural cells for personalised medicine.
Our efforts have traditionally incorporated multi-omics data, and disease-specific biomarkers for an AI model classification of patients subtypes, and we can also support clinical imaging data. We work closely with clinicians and industry partners for unraveling therapies tailored for specific patients.
Computational Services
We perform both bulk and single cell analysis of datasets from from client-supplied source or from public repositories with a focus on neuroscience. We use our own cloud services to handle raw datasets from QC steps all the way to biological interpretation. Depending on the needs of the user, we perform multiple analyses to provide insight in novel mechanism of action.
